GLP-1 Access and Hidradenitis Suppurativa Trials: What's Moving

Dermatology Times is spotlighting two linked practice problems this cycle: how patients actually secure access to GLP-1 receptor agonists, and how clinicians can connect people with hidradenitis suppurativa (HS) to clinical trials.

The pairing isn't accidental. GLP-1 agents — the drug class behind semaglutide and its relatives — have moved from endocrinology into mainstream dermatologic conversation, and HS sits at the intersection of metabolic disease and inflammatory skin disease where that conversation gets practical.

Why GLP-1 access matters in a dermatology clinic

Dermatology Times frames the GLP-1 story around access — the gap between a drug being available and a patient actually getting it, filling it, and affording it over time.

For dermatologists, that gap is now a waiting-room reality. Patients ask about GLP-1s for skin-adjacent reasons, and the practice-side questions land on the dermatology team:

• Which patients qualify, and who does the prescribing?
• What do insurers require before they approve a claim?
• How do prior authorization and supply constraints affect continuity of care?
• Where does coordination with primary care or endocrinology begin?

The coverage piece is the hard part. Access hinges on insurance design, formulary placement and persistence through the authorization process — administrative work that often determines whether a prescription becomes therapy.

What does this change for dermatologists?

The practical takeaway: dermatology practices are being pulled into GLP-1-adjacent care whether they planned for it or not. Knowing the access pathway — and being honest with patients about coverage hurdles — is becoming part of the consultation, not someone else's problem.

The hidradenitis suppurativa trial question

The second half of the coverage turns to HS, a chronic inflammatory condition marked by painful nodules, abscesses and sinus tracts, most often in intertriginous areas. HS remains one of the most undertreated conditions dermatologists manage, and current approved options don't reach every patient.

That's where trials come in. Dermatology Times walks through what exploring HS clinical trials involves:

• Identifying which patients are candidates — typically those with inadequate response to standard care
• Matching patients to studies by disease severity, most often tracked with Hurley staging
• Explaining enrollment logistics, follow-up burden and what randomization means in plain language
• Using trial referral as a genuine care option rather than a last resort

For patients with moderate-to-severe disease who have cycled through available therapies, a trial can be the route to an investigational agent they otherwise couldn't access.

Why these two stories run together

There's a clinical thread connecting them. Obesity and metabolic dysfunction are established associations of HS, and patients managing both often move through the same clinics. A dermatologist who understands GLP-1 access mechanics and knows how to open a trial conversation is, in effect, running a more complete HS practice.

The access story is administrative; the trial story is operational. Both reward practices that build the muscle early — coverage navigation on one side, referral relationships and screening workflows on the other.

As GLP-1 indications continue to widen and the HS pipeline keeps growing, Dermatology Times' dual focus signals where dermatology's practice burden is heading: more coordination, more coverage navigation, and more trial literacy at the point of care.